摘要
目的:基于以壳多糖酶3样蛋白1(chitinase-3-like protein 1,CHI3L1)为主要评价指标,观察化肝纤方联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法:将80例确诊为慢性乙型肝炎肝纤维化的患者采用随机数字表法的方式分为对照组和治疗组各40例,2组均采用一般西医综合治疗,治疗组在此基础上仅加用化肝纤方,疗程为8周,比较2组治疗前后的血清CHI3L1水平、肝功能(转氨酶、总胆红素)、肝纤4项、Fibrosis 4 Score(FIB-4指数)、肝脏硬度值(liver stiffness measurement,LSM)、乙肝病毒DNA(hepatitis B virus-DNA,HBV-DNA)转阴率、中医症状评分等观察指标。结果:治疗后治疗组血清CHI3L1水平、肝功能(转氨酶、总胆红素)、肝纤4项、FIB-4指数、肝脏硬度值、HBV-DNA转阴率、中医症状评分均低于对照组,差异有统计学意义。结论:化肝纤方联合恩替卡韦治疗慢性乙型肝炎相关肝纤维化有较好的临床疗效,可改善慢性乙型肝炎肝纤维化患者肝脏生理水平及肝纤维化程度,降低血清CHI3L1、肝纤4项、FBI-4指数、肝脏硬度值,提高乙肝病毒DNA转阴率,改善肝功能及临床症状,延缓疾病的进展,提高患者生存质量。
Objective:To observe the clinical efficacy of Huaganxian Decoction combined with entecavir in the treatment of liver fibrosis of chronic hepatitis B based on Chitinase-3-like protein 1(CHI3L1)as the main evaluation index.Methods:Eighty patients diagnosed with chronic hepatitis B fibrosis were randomly divided into control group and treatment group with 40 cases each,referring to the random number table.Both groups were given with integrated western medicine.The treatment group were given Huaganxian Decoction.The course of treatment was 8 weeks for the two groups.The serum CHI3L1 level,liver function(transaminase,total bilirubin),four items of liver fiber,fibrosis 4 score(FIB-4 index),liver stiffness measurement(LSM),hepatitis B virus DNA's(HBV-DNA)negative conversion rate and TCM symptom scores were compared before and after treatment.Results:After 8 weeks'treatment,serum CHI3L1 level,liver function(transaminase,total bilirubin),four items of liver fiber,FIB-4 Score,liver stiffness measurement,HBV-DNA's negative rate,and TCM symptom score in the treatment group were lower than those in the control group,the difference was statistically significant.Conclusion:Huaganxian Decoction combined with entecavir has a good clinical effect in the treatment of chronic hepatitis B-related liver fibrosis.It can improve the liver physiological level and liver fibrosis in patients with chronic hepatitis B liver fibrosis,reduce serum CHI3L1 level,four items of liver fiber,FBI-4 Score,liver stiffness measurement,increase the negative rate of HBV-DNA,improve liver function and clinical symptoms,delay the progress of the disease,and improve the quality of life of patients.
作者
牙程玉
蒋锐沅
胡晓
吴聪
毛德文
YA Cheng-yu;JIANG Rui-yuan;HU Xiao;WU Cong;MAO De-wen(Guangxi Traditional Chinese Medical University,Nanning 530001,China;The first affiliated hospital,Guangxi Traditional Chinese Medical University,Nanning 530023,China)
出处
《中国中医基础医学杂志》
CAS
CSCD
北大核心
2021年第4期608-612,共5页
JOURNAL OF BASIC CHINESE MEDICINE
基金
国家自然科学基金面上项目(81774236)-解毒化瘀颗粒通过miRNAsNF-κBROS调控NLRP3炎症体活化拮抗肝衰竭
国家自然科学基金资助项目(81460718)-暴发型肝衰竭pDCs-CTL/CD4+CD25+Treg免疫网络紊乱特征分析及解毒化瘀颗粒的干预效应
广西研究生教育创新计划资助项目(YCSY2019006)-化肝纤丸联合恩替卡韦分散片治疗慢性乙型肝炎肝纤维化的临床疗效研究。
关键词
化肝纤方
壳多糖酶3样蛋白1
慢性乙型肝炎
肝纤维化
临床疗效
Huaganxian decoction
Chitosanase 3-like protein 1
Chronic hepatitis B
Liver fibrosis
Clinical efficacy
